Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ROSEWOOD

- PMLiVE

AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

Follicular lymphoma affects around 15,000 people in the US every year

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

EU flag

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation would allow blood cancer patients to halve their daily pill intake

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer

Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

The aggressive form of lung cancer accounts for around 15% of all cases of the disease

- PMLiVE

Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma

The disease accounts for up to 30% of non-Hodgkin lymphoma cases

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

The mosquito-borne viral disease has been reported across many popular travel destinations

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

- PMLiVE

BMS receives CHMP recommendation for Breyanzi in follicular lymphoma

The disease is the second most common form of non-Hodgkin lymphoma, accounting for up to 30% of cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links